The United States Army Medical Research and Materiel Command (USAMRMC), Office of the Congressionally Directed Medical Research Programs (CDMRP) invites applications for funding for the FY05 Neurofibromatosis Research Program (NFRP) Therapeutic Development Awards.
The intent of the Therapeutic Development Award is to sponsor the development of therapeutics and the tools for their evaluation in preclinical model systems of NF1, NF2, and/or Schwannomatosis. The NFRP specifically seeks proposals in the following areas of preclinical drug development development and/or validation of high-throughput screens or models; identification of lead agents through screening of small molecule libraries; development, modification, and/or validation of preclinical models; or evaluation of novel and/or existing therapeutic modalities in preclinical model systems. The formation of multidisciplinary, multi-institutional consortia focused on a synergistic preclinical development project is strongly encouraged. Please see announcement for complete details of this award mechanism.
Although there are no total dollar amount restrictions to these awards, programmatic priority will be given to smaller-scale, cost-efficient projects with well-defined endpoints. Additionally, to foster the development of collaborative preclinical research teams, programmatic priority will be given to studies conducted by multidisciplinary, multi-institutional consortia. Funding can be requested for up to 3 years. Approximately $7 million (M) is available to fund the FY05 NFRP Therapeutic Development Awards. Depending on the number and quality of the applications, it is anticipated that one to four proposals will be funded.
Submission of the same research project to the FY05 NFRP under different award mechanisms or to other CDMRP programs is discouraged. The Government reserves the right to reject duplicative proposals.
Electronic submission is required. Proposals will be accepted only as PDF files submitted through the CDMRP eReceipt system. No paper copy submissions will be accepted. The CDMRP uses a two-tier review process for proposals: scientific peer review, followed by programmatic review. Details of both tiers of review can be found in the Full Text of Program Announcement.
Estimated timelines for the FY05 Therapeutic Development Award proposals are as follows: Full Proposal Submission Deadline: February 22, 2005, 5:00 p.m. Eastern Time; Peer Review: April, 2005; Programmatic Review: July, 2005; Award Start Date: Between September, 2005 and January, 2006.
For additional information or questions, please contact: Patricia A. Evans, Contracting/Grants Office, U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014, phone: (301) 619-7354, Fax: (301) 619-6662, email: email@example.com
Who can apply:
Eligible functional categories:
Military Medical Research and Development
Department of Defense (DOD) FY05 Department of Defense (DOD) FY05 Neurofibromatosis Research Program (NFRP) Therapeutic Development Award (TDA)
If you have problems accessing the full announcement, please contact:
US Army Medical Research Acquisition Activity, ATTN: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014